CO6290669A2 - Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina - Google Patents

Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina

Info

Publication number
CO6290669A2
CO6290669A2 CO10070917A CO10070917A CO6290669A2 CO 6290669 A2 CO6290669 A2 CO 6290669A2 CO 10070917 A CO10070917 A CO 10070917A CO 10070917 A CO10070917 A CO 10070917A CO 6290669 A2 CO6290669 A2 CO 6290669A2
Authority
CO
Colombia
Prior art keywords
disorder
depression
dementia
disease
anxiety
Prior art date
Application number
CO10070917A
Other languages
English (en)
Inventor
Silke Miller
Nanco Hefting
Eva Elstrup Jensen
Aneil Batra
Jin Chon
Original Assignee
Lundbeck & Co As H
Takeda Pharmaceuticls North America North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40285887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290669(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Takeda Pharmaceuticls North America North America filed Critical Lundbeck & Co As H
Publication of CO6290669A2 publication Critical patent/CO6290669A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan usos terapéuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapéuticamente aceptables.1.- Un método para tratar una enfermedad seleccionada entre retardo psicomotriz; depresión severa; trastorno distímico; ciclotimia; trastorno de ánimo debido a una condición médica generalizada; depresión inducida por sustancias; depresión recurrente; depresión de episodio único; depresión pediátrica; depresión atípica; depresión post-accidente cerebrovascular; depresión por extenuación; depresión asociada con dolor gastrointestinal, lBS, abuso, hostilidad, irritabilidad, fatiga, ansiedad (depresión ansiosa), enfermedad del Cuerpo de Lewy, enfermedad de Huntington, o esclerosis múltiple; trastorno de ansiedad generalizada asociado con dolor; trastorno afectivo estacional (SAD); depresión o ansiedad en pacientes con riesgo incrementado de hipertensión; depresión o ansiedad en pacientes con problemas de sueño; trastorno relacionado con el estrés; estrés agudo; demencia; deterioro cognitivo leve (MCI); demencia vascular; leucariosis; enfermedad de los vasos menores; deterioro cognitivo asociado con trastornos afectivos, depresión, depresión generalizada, trastorno depresivo grave, trastornos por ansiedad, trastorno por ansiedad generalizada, trastorno por pánico, trastorno obsesivo-compulsivo, esquizofrenia, enfermedad de Parkinson, demencia, demencia por SIDA, ADHD, deterioro de la memoria asociado con la edad, síndrome de Down, epilepsia, lesión cerebral traumática, síndrome de Asperger, y mutaciones del gen de la triptófano hidrolasa; trastorno disfórico pre-, peri- o post-menstrual; llanto patológico; autismo; obesidad; anorexia; bulimia; comilonas; trastorno del control de impulsos; trastorno explosivo intermitente; cleptomanía; piromanía; juego patológico; tricotilomanía; trastorno de la conducta; agotamiento; estrés; síndrome de fatiga crónica; trastorno del ritmo circadiano; trastorno del sueño; apnea del sueño; síndrome de hipopnea; alteraciones de la conducta; alteraciones de la conducta en la tercera edad; alteraciones de la conducta asociadas con la demencia; trastorno compulsivo y del espectro de atención asociado con ADHD, síndrome de Asperger y autismo; agresión y agitación en la demencia y la enfermedad de Alzheimer; resistencia a la insulina asociada con hiperactividad del eje HPA; síndrome del latigazo (whiplash); miedo a volar, a los ascensores o a los espacios restringidos; y ambliopía; comprendiendo el método la administración de una cantidad terapéuticamente efectiva de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sales de ésta terapéuticamenta aceptables (compuesto I) a un paciente que lo necesita.
CO10070917A 2007-12-14 2010-06-11 Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina CO6290669A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701791 2007-12-14
DKPA200701798 2007-12-17

Publications (1)

Publication Number Publication Date
CO6290669A2 true CO6290669A2 (es) 2011-06-20

Family

ID=40285887

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10070917A CO6290669A2 (es) 2007-12-14 2010-06-11 Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina

Country Status (18)

Country Link
US (3) US20110053978A1 (es)
EP (1) EP2231154A1 (es)
JP (1) JP2011506353A (es)
KR (1) KR20100092956A (es)
CN (1) CN102202666A (es)
AR (1) AR069904A1 (es)
AU (1) AU2008338059A1 (es)
BR (1) BRPI0819914A2 (es)
CA (1) CA2708786A1 (es)
CL (1) CL2008003709A1 (es)
CO (1) CO6290669A2 (es)
EA (1) EA201070737A1 (es)
IL (1) IL205965A0 (es)
MX (1) MX2010005795A (es)
NZ (1) NZ586010A (es)
SG (1) SG185984A1 (es)
TW (1) TW200938194A (es)
WO (1) WO2009076962A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52205B2 (sr) 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
KR20130060220A (ko) * 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CN104120177A (zh) * 2014-06-11 2014-10-29 杭州艾迪康医学检验中心有限公司 检测5-httlpr片段多态性的方法和引物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7732463B2 (en) * 2003-04-04 2010-06-08 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン

Also Published As

Publication number Publication date
AU2008338059A1 (en) 2009-06-25
IL205965A0 (en) 2010-11-30
MX2010005795A (es) 2010-08-31
TW200938194A (en) 2009-09-16
CN102202666A (zh) 2011-09-28
US20140296290A1 (en) 2014-10-02
EA201070737A1 (ru) 2010-12-30
SG185984A1 (en) 2012-12-28
JP2011506353A (ja) 2011-03-03
WO2009076962A1 (en) 2009-06-25
CL2008003709A1 (es) 2010-01-15
CA2708786A1 (en) 2009-06-25
KR20100092956A (ko) 2010-08-23
US20170087138A1 (en) 2017-03-30
EP2231154A1 (en) 2010-09-29
AR069904A1 (es) 2010-03-03
BRPI0819914A2 (pt) 2016-05-17
NZ586010A (en) 2012-08-31
US20110053978A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
JP7398836B2 (ja) Ｒ－ケタミンおよびその塩の医薬品としての応用
Wennberg et al. Sleep disturbance, cognitive decline, and dementia: a review
Marshansky et al. Sleep, chronic pain, and opioid risk for apnea
Yang et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
AR069260A1 (es) Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.
AU2013335613B2 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
CO6290669A2 (es) Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina
CO6450649A2 (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina
Bassetti et al. REM sleep behavior disorder
RU2008141076A (ru) Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами
Alhashimi et al. Comorbidity of epilepsy and depression: associated pathophysiology and management
AU2021206771A1 (en) Cognitive disorder prevention and therapy
ES2206400T3 (es) Utilizacion de modafinilo para la preparacion de un medicamento destinado a corregir los trastornos de la vigilia asociados a las miopatias.
CO6220958A2 (es) Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)fenil]-piperazina
Peter et al. REM sleep behavior disorder and excessive startle reaction to visual stimuli in a patient with pontine lesions
Rezaei-Nodehi et al. The effect of pleasant olfactory mental imagery on the incidence and extent of atelectasis in patients after open heart surgery
WO2021157682A1 (ja) 筋痛性脳脊髄炎／慢性疲労症候群治療剤
RU2022101512A (ru) Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1
JPWO2021001288A5 (es)
US20230381168A1 (en) Adjunctive therapy for depression
Rampello et al. The most frequent medical and surgical neuralgias: Physiopathology and clinical pictures
DiTommaso et al. Sleep Disorders in diseases of the central nervous system
Poluektov et al. Sleep and cognitive dysfunctions. Therapeutic approach
Gündoğmuş et al. Effect of Vortioxetine on Cognitive Functioning: A case report
Bertolín-Guillén et al. Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine

Legal Events

Date Code Title Description
FC Application refused